Meriofert Pfs

Follicle‑Stimulating Hormone and Luteinising Hormone, the active ingredients in Meriofert Pfs, are gonadotropins presented as an injectable solution for intramuscular or subcutaneous use. They are employed to stimulate ovarian follicle development and support ovulation in patients with infertility.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Meriofert Pfs, a gonadotropin preparation, is used in reproductive medicine to address disorders of follicular development and hormone deficiency.

- Infertility due to anovulation: promotes follicular growth and ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for assisted reproductive technologies: enhances the number of mature oocytes retrieved during IVF cycles. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal gonadal function in both sexes.

Administration of gonadotropin injections may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or bloating - Headache - Mild nausea - Transient ovarian cyst formation - Fatigue

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy (twins or higher order) - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe allergic reaction or anaphylaxis

When using Meriofert Pfs, clinicians should observe several safety measures.

- Monitor ovarian response: perform ultrasound and estradiol monitoring to adjust dose. - Avoid in uncontrolled thyroid disease: assess thyroid function before initiating therapy. - Use cautiously in patients with ovarian cysts or polycystic ovary syndrome: risk of exacerbation. - Assess for hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy considerations: not indicated for use during established pregnancy; treatment is stopped once pregnancy is confirmed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Pfs may interact with other medicines; awareness of key interactions helps optimise safety.

Major Interactions (Avoid): - Concomitant high‑dose estrogen therapy: may diminish gonadotropin efficacy. - Simultaneous use of other gonadotropins (e.g., hCG) at high doses: increases risk of ovarian hyperstimulation. - GnRH antagonists administered immediately before dosing: can blunt the intended hormonal response.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): monitor injection site for prolonged bleeding. - Thyroid hormone replacement: adjust dosing based on thyroid function tests. - Diuretics: observe fluid balance and blood pressure during treatment.